Aveo Pays $4M To End SEC Claims It Misled Investors
Massachusetts-based biotechnology company Aveo Pharmaceuticals Inc. will pay $4 million to settle the U.S. Securities and Exchange Commission's allegations it hid from investors the Food and Drug Administration's concerns over its...To view the full article, register now.
Already a subscriber? Click here to view full article